Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Burnout and career satisfaction among urologists specializing in sexual health
Schrup, Sarah E. , Hanley, Meg , May, Emily , Jones, James M. , Ziegelmann, Matthew , Gross, Martin , Schrup, Sarah, Jones, James M

The Journal of Sexual Medicine | April 15, 2025 | Volume: 22 | Issue: 5 | Pages: 869-876

10.1093/jsxmed/qdaf074 | PMID 40231422 Get It

Abstract Background While the rate of physician burnout has been characterized as relatively high among urologists compared to other specialties, a specific examination of burnout and predictors of burnout among urologists specializing in sexual medicine has not been conducted. Aim The aim of this study was to collect demographic characteristics of urologists specializing in sexual medicine, assess the occurrence of and risk factors for burnout, and characterize satisfaction with career, compensation and work-life balance. Methods We surveyed 96 urologists specializing in sexual medicine to characterize demographic and practice characteristics and assess their satisfaction with career aspects and levels of burnout. Univariable and multivariable modeling with stepwise variable selection was utilized to identify predictive variables of burnout. Outcomes The Copenhagen Burnout Inventory was used to assess personal burnout, work-related burnout, patient-related burnout, and overall burnout. Results Twenty-four percent (n = 23) of participants reported burnout with 35.4% (n = 34) reporting personal burnout, 38.5% (n = 37) reporting work-related burnout, and 24.0% (n = 23) reporting patient-related burnout. Younger age (P = 0.051), Black/African American or multiracial race compared to white race (P < 0.0001), Latino or Hispanic background (P = 0.034), female sex (P = 0.059), being unmarried (P = 0.047), and increased educational debt (0.030) were identified as predictive of overall burnout in adjusted analysis. Dissatisfaction with work-life balance was significantly related to an increase in all categories of burnout (P < 0.01). Clinical implications These findings may guide practice patterns and initiatives to support groups identified at increased risk of burnout, as well as function as a benchmark for future studies of burnout in the sexual medicine urology community. Strengths and limitations While this is the first study of burnout specifically among sexual medicine urologists and findings are consistent with the overall urology community, the small sample size may lead to a biased sample. Conclusion Several demographic and personal characteristics were identified to be predictive of burnout among the sexual medicine urology community, indicating opportunities for additional support.
Severe Hypercalcemia Associated With Perinatal Hypophosphatasia While Receiving Enzyme Replacement Therapy
Salama, Mostafa , Tebben, Peter , Salama, Mostafa , Nofal, Alaa Al , Tebben, Peter J.

JCEM Case Reports | April 15, 2025 | Volume: 3 | Issue: 5 | Pages: No page available

10.1210/jcemcr/luaf066 | PMID 40236614 Get It

Abstract Hypophosphatasia (HPP) is characterized by defective bone mineralization due to reduced function of tissue-nonspecific alkaline phosphatase (TNSALP) caused by pathogenic ALPL gene variants. Hypercalcemia is more common in the perinatal and infantile forms and may be mitigated or prevented with enzyme replacement therapy asfotase alfa (AA). Here, we report a patient who developed severe hypercalcemia while receiving AA. Hypercalcemia was initially managed with intravenous fluids, dietary calcium restriction, and maximizing AA dose. Despite these measures, she required an additional hospital admission, at which time calcitonin 4 IU/kg every 12 hours was initiated. On this regimen, her calcium normalized without recurrence of severe hypercalcemia. Over the subsequent 8 months, restrictions of calcium intake were slowly lifted, and calcitonin was tapered and discontinued with maintenance of calcium within the normal range. This case underscores the significance of vigilant monitoring of calcium levels and dietary intake in infants diagnosed with HPP. While calcitonin is typically not considered as a sustained treatment for hypercalcemia, the present case illustrates the efficacy of adjunct calcitonin therapy, in conjunction with restricted calcium intake and maximum AA dosing, in managing severe hypercalcemia in an infant with perinatal HPP.
Creating a Mammography Conversation Aid for Shared Decision‐Making Between Clinicians and Women Aged 75 and Older
Schonberg, Mara A. , Stout, Natasha K. , Stein, Sarah , Corey, Matthew T. , Jushchyshyn, Jessica A., Shah, Ria , Wolfson, Emily A , Mandelblatt, Jeanne S. , Matlock, Daniel D. , Schechter, Clyde B., Harris, Russell, LeStage, Barbara , Schoenborn, Nancy L. , Matlock, Daniel D , Montori, Víctor M. , Richman, Ilana B. , Harris, Russell, Jayasekera, Jinani C.

Journal of the American Geriatrics Society | April 15, 2025 | Volume: 73 | Issue: 7 | Pages: 2188-2195

10.1111/jgs.19466 | PMID 40231782 Get It

ABSTRACT Background Guidelines recommend primary care practitioners (“PCPs”) engage women ≥ 75 years in shared decision‐making (SDM) around mammography screening. Therefore, we aimed to develop a web‐based conversation aid about mammography screening for women ≥ 75 using output from established simulation models to provide screening outcomes based on > 23,000 combinations of individual women's health and breast cancer risk factors. Methods We used an end‐user centered design approach to develop a prototype web‐based conversation aid incorporating feedback. From July 2023 to April 2024, 10 PCPs from a Boston‐area health system and a safety‐net hospital used the prototype aid during encounters with women ≥ 75 without breast cancer or dementia ( n = 30; 1–5 patients per PCP). We observed aid use and assessed clinician effort to involve patients in SDM using OPTION5 (assesses five components of SDM, scores range 0–100). We surveyed PCPs and patients about the aid's acceptability. Patients completed the SDM‐process scale (scores range 0–4) to rate the SDM quality experienced. Participants' comments were subject to thematic analysis. Results Of 10 PCP ‐participants, seven were female and four were community‐based. Of 30 patient‐participants, 22 (73%) were non‐Hispanic White, 9 (30%) had ≥ 2 Charlson comorbidities and mean age was 78.5 years ( SD 2.8). Nine PCPs agreed that the aid helped them with SDM and was easy‐to‐use; six felt it had too much information; and seven planned to continue using the aid. Patients rated the SDM ‐process highly (scores = 3.0 [ SD 0.9]) and we observed high SDM (mean OPTION5 = 77.9 [ SD 20.6]). Participants felt the aid was “empowering” and “helpful for decision‐making.” After SDM discussions, seven patients intended to stop screening, nine to screen less frequently, and 14 to continue screening regularly. Conclusions We developed a novel conversation aid that supports SDM about mammography screening with women ≥ 75 years. Lessons learned will guide revisions of a final tool for testing in a clinical trial.
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , Ali, Hawa M. , McCalla, Monet, Roitman, Ariel , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Dailey, Seth H. , Ekbom, Dale C. , Bowen, Andrew Jay , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Dailey, Seth H , Ekbom, Dale , Awadallah, Andrew , Bayan, Semirra L. , Koster, Matthew J.

The Laryngoscope | April 15, 2025 | Volume: 135 | Issue: 9 | Pages: 3280-3286

10.1002/lary.32181 | PMID 40231755 Get It

ABSTRACTObjectiveWhile endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.MethodsThis was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.ResultsA total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).ConclusionLWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.
Axillary Lymph Node Dissection With and Without Immediate Lymphatic Reconstruction: Association With Drain Days and Seromas
Brown, Samantha , McLaughlin, Sarah A. , Vijayasekaran, Aparna , Li, Zhuo , Price, M, Jakub, James W. , Brown, Samantha J , Forte, Antonio Jorge , Piltin, Mara A. , Price, Monica M, Jakub, James W , Boughey, Judy C. , Forte, Antonio J. , Hieken, Tina J. , Price, Monica M.

The American Surgeon™ | April 15, 2025 | Volume: 91 | Issue: 8 | Pages: 1323-1330

10.1177/00031348251332692 | PMID 40231739 Get It

Background: Immediate lymphatic reconstruction (ILR) via lymphovenous anastomosis is performed in patients undergoing axillary lymph node dissection (ALND) to minimize the risk of lymphedema. Following ALND, drains are placed to prevent seromas, while prolonged drain days are associated with increased risk of infection. The study aim was to determine the impact of ILR on the number of drain days following ALND in patients with breast cancer. Methods: We report a post-hoc analysis of a prospective trial (April 2018-January 2023) comparing patients with breast cancer who underwent ALND with ILR (intervention arm) vs ALND without ILR (control arm). Wilcoxon rank sum test and chi-squared or Fisher’s exact tests compared continuous and categorical variables, respectively. Multivariable quantile regression models evaluated the difference in drain days and days until drain removal criteria were met with covariates adjusted. Results: Data from 214 patients were analyzed (n = 115 interventional arm, n = 99 control arm). The intervention arm had a median of 15 axillary drain days compared to 11 days in the control arm ( P = .001). There was no significant difference between groups when measuring drain days based on the date the drain met removal criteria, rather than actual drain removal date. Seroma incidence was lower in the intervention arm (3.5%) vs the control arm (12.1%) ( P = .017) without a statistical difference in incidence of infection. Conclusion: ALND with ILR does not decrease the number of drain days compared to ALND without ILR in patients with breast cancer, although we found the incidence of seromas to be lower without increase in incidence of infection.
Why Core GRADE is needed: introduction to a new series in The BMJ
Guyatt, Gordon , Hultcrantz, Monica , Agoritsas, Thomas , Iorio, Alfonso , Vandvik, Per Olav , Iorio, Alfonso , Guyatt, Gordon , Montori, Víctor M.

BMJ | April 15, 2025 | Volume: 389 | Issue: No issue available | Pages: e081902

10.1136/bmj-2024-081902 | PMID 40233981 Get It

Efficacy and safety of inclisiran based on background lipid-lowering treatment
Köenig, Wolfgang , Leiter, Lawrence A. , Ray, Kausik K. , Schwartz, Gregory G. , Han, Jackie , Conde, Lorena Garcia , Wright, R Scott, Landmesser, Ulf , Koenig, Wolfgang , Leiter, Lawrence A , Conde, Lorena Garcia , Ray, Kausik K , Landmesser, Ulf , Raal, Frederick J.

European Journal of Preventive Cardiology | April 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf214 | PMID 40242982 Get It

Abstract Aims To evaluate whether the effect of inclisiran to lower LDL-C varied by background lipid-lowering therapy (LLT). Methods and results In ORION-10 and ORION-11 Phase 3 trials, patients (N = 3178) with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents were randomized 1:1 to receive inclisiran or placebo on Day 1, Day 90, and 6-monthly thereafter. In this pooled post hoc analysis, patients were stratified by baseline combination therapy [statin plus ezetimibe (n = 214; 6.7%)], monotherapy [statin (n = 2711; 85.3%) or ezetimibe (n = 54; 1.7%)], or neither LLT [none (n = 199; 6.3%)] into therapy groups with/without other LLT. Stratification by baseline statin intensity was also performed (N = 3155). Relative and absolute changes in LDL-C were assessed. Mean (±SD) baseline LDL-C was 2.7 mmol/L (±1.0), 2.6 mmol/L (±0.9), 3.7 mmol/L (±1.7), and 4.1 mmol/L (±1.5) among patients receiving combination, statin, ezetimibe, or neither LLT, respectively. In these categories, mean (95% confidence interval) time-adjusted, placebo-corrected percentage change in LDL-C after Day 90 to Day 540 with inclisiran were −57.0% (−63.8, −50.1), −51.5.% (−53.4, −49.7), −50.5.% (−59.6, −41.5), and −43.1% (−48.7, −37.6); corresponding absolute changes were −1.5 mmol/L (−1.7, −1.3), −1.3 mmol/L (−1.4, −1.3), −1.7 mmol/L (−2.0, −1.4), and −1.7 mmol/L (−1.9, −1.5). Conclusion Sustained and effective LDL-C lowering with inclisiran was observed irrespective of background LLT treatment. Inclisiran was overall well tolerated with all background LLT treatments, consistent with its established safety profile.
National trends in prescription drug expenditures and projections for 2025
Tichy, Eric M. , Rim, Matthew H, Cuéllar, Sandra , Tadrous, Mina , Schumock, Glen T., Johnson, Thomas J., Newell, Mary Kate, Hoffman, James M.

American Journal of Health-System Pharmacy | April 15, 2025 | Volume: 82 | Issue: 14 | Pages: 806-821

10.1093/ajhp/zxaf092 | PMID 40263109 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2025 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2025 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, specialty drugs and vaccines. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2024 were made based on a combination of quantitative analyses and expert opinion. Results In 2024, overall pharmaceutical expenditures in the US grew 10.2% compared to 2023, for a total of $805.9 billion. Utilization (a 7.9% increase) and new drugs (a 2.5% increase) drove this increase, while prices remained flat (a 0.2% decrease). Semaglutide was the top drug in 2024, followed by tirzepatide and adalimumab. Drug expenditures were $39.0 billion (a 4.9% increase) and $158.2 billion (a 14.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, increased utilization drove growth, with a small contribution from new products, while prices remained flat. In nonfederal hospitals, new products, price, and new volume each contributed modestly to growth in spend. Several new drugs that will influence spending are expected to be approved in 2025. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2025, we expect overall prescription drug spending to rise by 9.0 to 11.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 2.0% to 4.0% increase, respectively, compared to 2024. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.
Road Map to Better Depression Care: A Road No Longer Less Traveled
Frye, Mark A.

Focus | April 15, 2025 | Volume: 23 | Issue: 2 | Pages: 123-124

10.1176/appi.focus.20250007 | PMID 40235612 Get It

Symptom Severity and Treatment Needs Among Racial Groups Seeking Treatment at a Mood Outcomes Program
Sánchez-Ruiz, Jorge A. , Straub, Jason , Zandi, Peter P. , Ajilore, Olusola , Coombes, Brandon J. , Strakowski, Stephen M. , Taylor-Desir, Monica , Taylor-Desir, Monica J., Coombes, Brandon J , Sanchez-Ruiz, Jorge A , Ajilore, Olusola , Frye, Mark A.

Focus | April 15, 2025 | Volume: 23 | Issue: 2 | Pages: 156-162

10.1176/appi.focus.20240051 | PMID 40235616 Get It